Releases

Category:

Nov 30, 2016 Corporate Releases	U.S. FDA accepts for review a supplemental New Drug Application to expand labelling of Abilify Maintena® (aripiprazole) for the treatment of Bipolar I disorder
Nov 15, 2016 Corporate Releases	Lundbeck increases its share capital by 7,047 shares (0.0036 % of outstanding shares) as a result of exercise of employee warrants
Nov 7, 2016 Corporate Releases	Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Nov 3, 2016 Corporate Releases	Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Nov 2, 2016 Corporate Releases	Lundbeck raises its 2016 financial guidance based on improved sales and profitability
Oct 8, 2016 Corporate Releases	U.S. FDA approves Carnexiv™ (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
Sep 24, 2016 Corporate Releases	US FDA approves labelling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia
Sep 22, 2016 Corporate Releases	Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease
Sep 12, 2016 Corporate Releases	Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Sep 8, 2016 Corporate Releases	The General Court of the EU upholds the European Commission's 2013 fining decision against Lundbeck
Sep 6, 2016 Corporate Releases	Lundbeck increases its share capital by 97,349 shares (0.0493 % of outstanding shares) as a result of exercise of employee warrants
Aug 25, 2016 Corporate Releases	Correction of Corporate Release No. 595 - Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Aug 25, 2016 Corporate Releases	Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Aug 24, 2016 Corporate Releases	Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016
Jun 2, 2016 Corporate Releases	Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
May 31, 2016 Corporate Releases	Total number of voting rights and share capital in H. Lundbeck A/S as of 31 May 2016
May 30, 2016 Corporate Releases	Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
May 25, 2016 Corporate Releases	Correction of Corporate Release No. 589 - H. Lundbeck A/S increases its share capital by 173,940 shares (0.0881 % of outstanding shares) as a result of employee warrant exercise
May 25, 2016 Corporate Releases	H. Lundbeck A/S increases its share capital by 173,940 shares (0.0881 % of outstanding shares) as a result of employee warrant exercise
May 17, 2016 Corporate Releases	Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
May 13, 2016 Corporate Releases	Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
May 12, 2016 Corporate Releases	Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
May 11, 2016 Corporate Releases	2016 guidance raised based on solid sales performance and improved profitability
Mar 31, 2016 Corporate Releases	Lundbeck held its Annual General Meeting on 31 March 2016 at the company's registered office
Mar 29, 2016 Corporate Releases	Lundbeck and Takeda receive Complete Response Letter by the FDA for Brintellix® (vortioxetine) sNDA
Mar 11, 2016 Corporate Releases	Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
Mar 8, 2016 Corporate Releases	Notice of Annual General meeting
Feb 29, 2016 Corporate Releases	Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016
Feb 23, 2016 Corporate Releases	H. Lundbeck A/S increases its share capital by 40,104 shares (0.0203 % of outstanding shares) as a result of employee warrant exercise
Feb 10, 2016 Corporate Releases	Annual Report 2015 for H. Lundbeck A/S
Feb 10, 2016 Corporate Releases	Solid sales performance in 2015 and return to profitability in 2016
Feb 8, 2016 Corporate Releases	US FDA accepts for review Otsuka and Lundbeck's sNDA filing for labelling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia
Feb 4, 2016 Corporate Releases	FDA Psychopharmacologic Drug Advisory Committee supports the effectiveness of Brintellix® (vortioxetine) in treating certain aspects of cognitive dysfunction in Major Depressive Disorder (MDD)

In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request. Please contact us here.

Choose region and then country

Other Lundbeck sites

Global contacts

Category:

Choose region and then country

Other Lundbeck sites

Global contacts

Releases

Category:

Subscribe

Keep updated